Cell Therapy: Cancer’s New Arsenal
Though several therapeutic, biotech, and medtech developments are changing the oncology landscape, in-vivo CAR-T cell therapy stands out for its precision, accessibility, and upscaling capabilities. A step up from ex vivo CAR-T cell therapy, it takes precedence due to its improved toxicity management, manufacturing parameters, and broader scope of clinical applications. With evolving technologies and regulatory frameworks shaping its future, its impact is expanding beyond cancer to autoimmune diseases, tumors, and non-cancer indications.
Other Forms of Cell Therapies Changing the Landscape of Cancer Treatment
Tumor-Infiltrating Lymphocyte (TIL) Therapy: Under this approach, immune cells that naturally invade the patient’s tumor are harvested, expanded in labs, and then reinfused back into the patient.
Allogeneic Cell Therapies: Also known as the off-the-shelf or next-generation cell therapy, it follows the CAR-T cell therapy treatment pattern, but instead of using a patient’s cells, it borrows cells from healthy donors. They are then engineered to reduce the risk of immune rejection.
Self-Amplifying RNA (saRNA): Similar to modified mRNA, saRNA is driving the next wave of innovation in cellular therapy for cancer. Apart from increasing the safety levels of cell therapies, they are also helping manufacturers on the cost and efficacy fronts.
More developments marking progress in oncology:
[newsletter_cta]